Autologous cancer vaccine: a novel formulation.
A novel cancer vaccine consisting of fixed autologous cancer tissue-fragments, microparticles encapsulating cytokines, and an adjuvant was developed. In a Phase I/IIa clinical trial, vaccination to patients after resection of hepatocellular carcinoma induced significantly longer time before the first recurrence than that in historical control patients operated in the same department (P < 0.05). This formulation will be promising against recurrence of many types of human cancers.
Ohno
Tadao
T
RIKEN Cell Bank, RIKEN (The Institute of Physical and Chemical Research), Koyadai 3-1-1, Tsukuba Science City, Ibaraki 305-0074, Japan. tad-ohno@rtc.riken.go.jp
D001500:BCG Vaccine / Q000737:chemistry / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000737:chemistry; D002272:Carcinoembryonic Antigen / Q000145:classification / Q000276:immunology; D003131:Combined Modality Therapy / Q000379:methods; D006801:Humans; D008297:Male; D008545:Melanoma / Q000601:surgery / Q000628:therapy; D008875:Middle Aged; D008954:Models, Biological; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D009369:Neoplasms / Q000276:immunology / Q000628:therapy; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
D001500:BCG Vaccine; D019496:Cancer Vaccines; D002272:Carcinoembryonic Antigen